Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study "AFASAK I"


Phase N/A Results


Patients in the warfarin group (n=335) experienced a total of five thromboembolic complications; patients in the aspirin group (n=336) experienced 20 thromboembolic complications; and patients in the placebo group (n=336) experienced 21 thromboembolic complications. The yearly frequency of events (warfarin at 2.0%; aspirin and placebo at 5.5%) was statistically significant (p>0.05). An intention-to-treat analysis of the 71 total deaths in the study (including those who withdrew from the study) showed no difference in either vascular or total mortality.